Optimized Ablation of the Posterior Wall in Persistent Atrial Fibrillation
Recruiting · NCT07122336 · Interventional (participants receive a specific treatment) · Lead sponsor: Shanghai Chest Hospital
View the official record on ClinicalTrials.gov →Interventions studied
EGMPVIPWI
What this trial is about
The design of this study is an intervention, randomized, controlled study and contains three randomized groups：（1）PVI group；（2）PVI+PWI group;（3）PVI+PWI+EGM group.
Who can take part
Age range
18 Years to 80 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age ≥18 years
- First-time ablation for persistent atrial fibrillation (PsAF)
- Persistent AF definition: Sustained episodes lasting ≥7 days but ≤3 years (including episodes requiring pharmacologic or electrical cardioversion after ≥7 days)
- Symptomatic AF with intolerance to at least one antiarrhythmic drug (AAD)
- Documented PsAF episode: At least one recorded PsAF episode within the last 2 years prior to enrollment, confirmed by: ECG,Holter monitorin, Loop recorder, Telemetry, Transtelephonic monitoring (TTM),Implantable device
- Ability and willingness to provide written informed consent
- Compliance with all study follow-up requirements
Exclusion criteria
- Paroxysmal AF: Episodes lasting \<7 days (or requiring pharmacologic/electrical cardioversion \<7 days)
- Long-standing persistent AF: Continuous AF duration \>3 years
- No prior attempt/pursuit of cardioversion or sinus rhythm maintenance
- Contraindications to systemic anticoagulation
- Pregnancy
- Advanced renal or hepatic failure
- Severe valvular heart disease or cyanotic congenital heart disease
- Hypertrophic cardiomyopathy (HCM)
Where it is running
1 location listed.
- Shanghai Chest Hospital - Shanghai, China